GlassScriptPhysician profile
Thomas W Chu
NPI 1669842787
$15,219.99
in general payments reported to CMS, 2019-2025
23 companies · $1,669 in 2025
The $1,669 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,436 · 2020: $426 · 2021: $310 · 2022: $527 · 2023: $238 · 2024: $9,614 · 2025: $1,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,500 · Food and Beverage: $2,665 · Travel and Lodging: $1,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,500.00 |
| Food and Beverage | $2,665.47 |
| Travel and Lodging | $1,355.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $9,321.19 | 2020-2025 | |
| Abbvie INC. | $1,574.86 | 2019-2025 | Skyrizi |
| Celgene Corporation | $1,311.35 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $445.00 | 2019-2025 | Dupixent |
| Organogenesis INC. | $328.80 | 2021-2025 | Puraply Wound Matrix |
| Janssen Biotech, INC. | $283.41 | 2019-2025 | Tremfya |
| Ucb, INC. | $241.71 | 2024-2025 | Bimzelx |
| Lifenet Health | $225.10 | 2023-2025 | Theragenesis Wound Matrix |
| Novartis Pharmaceuticals Corporation | $189.27 | 2019-2025 | |
| Amgen INC. | $186.74 | 2024-2025 | Otezla, Otezla |
| Genzyme Corporation | $173.09 | 2019-2025 | |
| Bioventus LLC | $148.40 | 2022-2023 | |
| Epi Health, LLC | $145.88 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $109.63 | 2019 | |
| Janssen Scientific Affairs, LLC | $103.79 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $84.35 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Biofrontera INC. | $82.94 | 2019-2021 | |
| Leo Pharma INC. | $81.31 | 2025 | Adbry |
| Incyte Corporation | $71.25 | 2025 | Opzelura |
| Lilly USA, LLC | $64.62 | 2019-2021 | |
| Organon LLC | $19.90 | 2025 | Vtama |
| Teva Pharmaceuticals USA, INC. | $15.87 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.